Bone health in inflammatory bowel disease

References

• Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015 Dec;12(12):720–727. doi: 10.1038/nrgastro.2015.150
   PubMed Web of Science ®Google Scholar
• Cosnes J, Gower-Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011 May;140(6):1785–1794. doi: 10.1053/j.gastro.2011.01.055
   PubMed Web of Science ®Google Scholar
• Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults. Gastroenterology. 2008 Dec;135(6):1907–1913. doi: 10.1053/j.gastro.2008.09.012
   PubMed Web of Science ®Google Scholar
• Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012 Jan;142(1):46–54.e42. quiz e30. doi: 10.1053/j.gastro.2011.10.001
   PubMed Web of Science ®Google Scholar
• Ott C, Schölmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol. 2013 Oct;10(10):585–595. doi: 10.1038/nrgastro.2013.117
   PubMed Web of Science ®Google Scholar
• Rogler G, Singh A, Kavanaugh A, et al. Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management. Gastroenterology. 2021 Oct;161(4):1118–1132. doi: 10.1053/j.gastro.2021.07.042
   PubMed Web of Science ®Google Scholar
• Vavricka SR, Schoepfer A, Scharl M, et al. Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2015 Aug;21(8):1982–1992. doi: 10.1097/MIB.0000000000000392
   PubMed Web of Science ®Google Scholar
• Argollo M, Gilardi D, Peyrin-Biroulet C, et al. Comorbidities in inflammatory bowel disease: a call for action. Lancet Gastroenterol Hepatol. 2019 Aug;4(8):643–654. doi: 10.1016/S2468-1253(19)30173-6
   PubMed Web of Science ®Google Scholar
• Bähler C, Schoepfer AM, Vavricka SR, et al. Chronic comorbidities associated with inflammatory bowel disease: prevalence and impact on healthcare costs in Switzerland. Eur J Gastroenterol Hepatol. 2017 Aug;29(8):916–925. doi: 10.1097/MEG.0000000000000891
   PubMed Web of Science ®Google Scholar
• Osteoporosis Prevention, Screening, and Diagnosis: ACOG Clinical Practice Guideline No. 1. Obstet Gynecol. 2021 Sep 1;138(3):494–506. doi: 10.1097/AOG.0000000000004514
   PubMed Web of Science ®Google Scholar
• Fink HA, MacDonald R, Forte ML, et al. Long-term drug therapy and drug discontinuations and holidays for osteoporosis fracture prevention: a systematic review. Ann Intern Med. 2019 Jul 2;171(1):37–50. doi: 10.7326/M19-0533
   PubMed Web of Science ®Google Scholar
• Adult Positions [Internet]. Iscd; [ updated 2019 May 28; cited 2023 Jul 31]. Available from: https://iscd.org/learn/official-positions/adult-positions/.
   Google Scholar
• Sebro R, Ashok SS. A statistical approach regarding the diagnosis of osteoporosis and osteopenia from DXA: are we underdiagnosing osteoporosis? JBMR Plus. 2021 Feb;5(2):e10444. doi: 10.1002/jbm4.10444
   PubMedGoogle Scholar
• Pediatric Positions [Internet]. Iscd; [ updated 2019 May 28; cited 2023 Jul31]. Available from: https://iscd.org/learn/official-positions/pediatric-positions/.
   Google Scholar
• Chedid VG, Kane SV. Bone health in patients with inflammatory bowel diseases. J Clin Densitom. 2020 Apr;23(2):182–189. doi: 10.1016/j.jocd.2019.07.009
   PubMed Web of Science ®Google Scholar
• Canavese F, Samba A, Rousset M. Pathological fractures in children: diagnosis and treatment options. Orthop Traumatol Surg Res. 2016 Feb;102(1 Suppl):S149–59. doi: 10.1016/j.otsr.2015.05.010
   PubMed Web of Science ®Google Scholar
• Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007 Mar;22(3):465–475. doi: 10.1359/jbmr.061113
   PubMed Web of Science ®Google Scholar
• Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int. 2005 Mar;16(2):S3–7. doi: 10.1007/s00198-004-1702-6
   PubMedGoogle Scholar
• Katsoulis M, Benetou V, Karapetyan T, et al. Excess mortality after hip fracture in elderly persons from Europe and the USA: the CHANCES project. J Intern Med. 2017 Mar;281(3):300–310. doi: 10.1111/joim.12586
   PubMed Web of Science ®Google Scholar
• Piñar-Gutierrez A, García-Fontana C, García-Fontana B, et al. Obesity and bone health: A complex relationship. Int J Mol Sci. 2022 Jul 27;23(15):8303. doi: 10.3390/ijms23158303
   PubMed Web of Science ®Google Scholar
• Wright NC, Looker AC, Saag KG, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res. 2014 Nov;29(11):2520–2526. doi: 10.1002/jbmr.2269
   PubMed Web of Science ®Google Scholar
• Szafors P, Che H, Barnetche T, et al. Risk of fracture and low bone mineral density in adults with inflammatory bowel diseases. A systematic literature review with meta-analysis. Osteoporos Int. 2018 Nov;29(11):2389–2397. doi: 10.1007/s00198-018-4586-6
   PubMed Web of Science ®Google Scholar
• van Bodegraven AA, Bravenboer N. Perspective on skeletal health in inflammatory bowel disease. Osteoporos Int. 2020 Apr;31(4):637–646. doi: 10.1007/s00198-019-05234-w
   PubMed Web of Science ®Google Scholar
• Auvin S, Molinié F, Gower-Rousseau C, et al. Incidence, clinical presentation and location at diagnosis of pediatric inflammatory bowel disease: a prospective population-based study in northern France (1988-1999). J Pediatr Gastroenterol Nutr. 2005 Jul;41(1):49–55. doi: 10.1097/01.MPG.0000162479.74277.86
   PubMed Web of Science ®Google Scholar
• Kelsen J, Baldassano RN. Inflammatory bowel disease: the difference between children and adults. Inflamm Bowel Dis. 2008 Oct;14(2):S9–11. doi: 10.1097/00054725-200810001-00005
   PubMedGoogle Scholar
• Langholz E, Munkholm P, Krasilnikoff PA, et al. Inflammatory bowel diseases with onset in childhood. Clinical features, morbidity, and mortality in a regional cohort. Scand J Gastroenterol. 1997 Feb;32(2):139–147. doi: 10.3109/00365529709000184
   PubMed Web of Science ®Google Scholar
• Walther F, Fusch C, Radke M, et al. Osteoporosis in pediatric patients suffering from chronic inflammatory bowel disease with and without steroid treatment. J Pediatr Gastroenterol Nutr. 2006 Jul;43(1):42–51. doi: 10.1097/01.mpg.0000228105.91240.80
   PubMed Web of Science ®Google Scholar
• Bartram SA, Peaston RT, Rawlings DJ, et al. Mutifactorial analysis of risk factors for reduced bone mineral density in patients with Crohn’s disease. World J Gastroenterol. 2006 Sep 21;12(35):5680–5686. doi: 10.3748/wjg.v12.i35.5680
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Bollani S, Bettica P, et al. Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn’s disease and ulcerative colitis. J Intern Med. 2000 Jan;247(1):63–70. doi: 10.1046/j.1365-2796.2000.00582.x
   PubMed Web of Science ®Google Scholar
• Abitbol V, Roux C, Chaussade S, et al. Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology. 1995 Feb;108(2):417–422. doi: 10.1016/0016-5085(95)90068-3
   PubMed Web of Science ®Google Scholar
• Pollak RD, Karmeli F, Eliakim R, et al. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol. 1998 Sep;93(9):1483–1490. doi: 10.1111/j.1572-0241.1998.468_q.x
   PubMed Web of Science ®Google Scholar
• Wada Y, Hisamatsu T, Naganuma M, et al. Risk factors for decreased bone mineral density in inflammatory bowel disease: a cross-sectional study. Clin Nutr. 2015 Dec;34(6):1202–1209. doi: 10.1016/j.clnu.2015.01.003
   PubMed Web of Science ®Google Scholar
• Ali T, Lam D, Bronze MS, et al. Osteoporosis in inflammatory bowel disease. Am j med. 2009 Jul;122(7):599–604. doi: 10.1016/j.amjmed.2009.01.022
   PubMed Web of Science ®Google Scholar
• Bjarnason I, Macpherson A, Mackintosh C, et al. Reduced bone density in patients with inflammatory bowel disease. Gut. 1997 Feb;40(2):228–233. doi: 10.1136/gut.40.2.228
   PubMed Web of Science ®Google Scholar
• Harbord M, Annese V, Vavricka SR, et al. The first European evidence-based Consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016 Mar;10(3):239–254. doi: 10.1093/ecco-jcc/jjv213
   PubMed Web of Science ®Google Scholar
• Kärnsund S, Lo B, Bendtsen F, et al. Systematic review of the prevalence and development of osteoporosis or low bone mineral density and its risk factors in patients with inflammatory bowel disease. World J Gastroenterol. 2020 Sep 21;26(35):5362–5374. doi: 10.3748/wjg.v26.i35.5362
   PubMed Web of Science ®Google Scholar
• Tsai MS, Lin CL, Tu YK, et al. Risks and predictors of osteoporosis in patients with inflammatory bowel diseases in an Asian population: a nationwide population-based cohort study. Int J Clin Pract. 2015 Feb;69(2):235–241. doi: 10.1111/ijcp.12526
   PubMed Web of Science ®Google Scholar
• Haugeberg G, Vetvik K, Stallemo A, et al. Bone density reduction in patients with Crohn disease and associations with demographic and disease variables: cross-sectional data from a population-based study. Scand J Gastroenterol. 2001 Jul;36(7):759–765. doi: 10.1080/003655201300192030
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark. Osteoporos Int. 2005 Feb;16(2):134–141. doi: 10.1007/s00198-004-1680-8
   PubMed Web of Science ®Google Scholar
• Hidalgo DF, Boonpheng B, Phemister J, et al. Inflammatory bowel disease and risk of osteoporotic fractures: a meta-analysis. Cureus. 2019 Sep 30;11(9):e5810. doi: 10.7759/cureus.5810
   PubMed Web of Science ®Google Scholar
• Lo B, Holm JP, Vester-Andersen MK, et al. Incidence, risk factors and evaluation of osteoporosis in patients with inflammatory bowel disease: a Danish population-based inception cohort with 10 years of follow-up. J Crohns Colitis. 2020 Jul 30;14(7):904–914. doi: 10.1093/ecco-jcc/jjaa019
   PubMed Web of Science ®Google Scholar
• Adachi JD, Rostom A. Metabolic bone disease in adults with inflammatory bowel disease. Inflamm Bowel Dis. 1999 Aug;5(3):200–211. doi: 10.1097/00054725-199908000-00009
   PubMed Web of Science ®Google Scholar
• Abreu MT, Kantorovich V, Vasiliauskas EA, et al. Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn’s disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density. Gut. 2004 Aug;53(8):1129–1136. doi: 10.1136/gut.2003.036657
   PubMed Web of Science ®Google Scholar
• Burisch J, Katsanos KH, Christodoulou DK, et al. Natural disease course of ulcerative Colitis during the first Five years of follow-up in a European population-based inception cohort-an Epi-IBD study. J Crohns Colitis. 2019 Feb 1;13(2):198–208. doi: 10.1093/ecco-jcc/jjy154
   PubMed Web of Science ®Google Scholar
• Burisch J, Kiudelis G, Kupcinskas L, et al. Natural disease course of Crohn’s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. Gut. 2019 Mar;68(3):423–433. doi: 10.1136/gutjnl-2017-315568
   PubMed Web of Science ®Google Scholar
• Lunney PC, Kariyawasam VC, Wang RR, et al. Smoking prevalence and its influence on disease course and surgery in Crohn’s disease and ulcerative colitis. Aliment Pharmacol Ther. 2015 Jul;42(1):61–70. doi: 10.1111/apt.13239
   PubMed Web of Science ®Google Scholar
• Jahnsen J, Falch JA, Aadland E, et al. Bone mineral density is reduced in patients with Crohn’s disease but not in patients with ulcerative colitis: a population based study. Gut. 1997 Mar;40(3):313–319. doi: 10.1136/gut.40.3.313
   PubMed Web of Science ®Google Scholar
• Ghosh S, Cowen S, Hannan WJ, et al. Low bone mineral density in Crohn’s disease, but not in ulcerative colitis, at diagnosis. Gastroenterology. 1994 Oct;107(4):1031–1039. doi: 10.1016/0016-5085(94)90227-5
   PubMed Web of Science ®Google Scholar
• Farraye FA, Melmed GY, Lichtenstein GR, et al. ACG clinical guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol. 2017 Feb;112(2):241–258. doi: 10.1038/ajg.2016.537
   PubMed Web of Science ®Google Scholar
• Bartko J, Reichardt B, Kocijan R, et al. Inflammatory bowel disease: a nationwide study of hip fracture and mortality risk after hip fracture. J Crohns Colitis. 2020 Sep 16;14(9):1256–1263. doi: 10.1093/ecco-jcc/jjaa052
   PubMed Web of Science ®Google Scholar
• Ahn HJ, Kim YJ, Lee HS, et al. High risk of fractures within 7 years of diagnosis in Asian patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2022 May;20(5):e1022–e1039. doi: 10.1016/j.cgh.2021.06.026
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Blanchard JF, Leslie W, et al. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med. 2000 Nov 21;133(10):795–799. doi: 10.7326/0003-4819-133-10-200011210-00012
   PubMed Web of Science ®Google Scholar
• Card T, West J, Hubbard R, et al. Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study. Gut. 2004 Feb;53(2):251–255. doi: 10.1136/gut.2003.026799
   PubMed Web of Science ®Google Scholar
• Loftus EV Jr., Achenbach SJ, Sandborn WJ, et al. Risk of fracture in ulcerative colitis: a population-based study from Olmsted County, Minnesota. Clin Gastroenterol Hepatol. 2003 Nov;1(6):465–473. doi: 10.1016/S1542-3565(03)00185-X
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Mosekilde L. Fracture risk in patients with celiac disease, Crohn’s disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol. 2002 Jul 1;156(1):1–10. doi: 10.1093/aje/kwf007
   PubMed Web of Science ®Google Scholar
• Ludvigsson JF, Mahl M, Sachs MC, et al. Fracture risk in patients with inflammatory bowel disease: a nationwide population-based cohort study from 1964 to 2014. Am J Gastroenterol. 2019 Feb;114(2):291–304. doi: 10.14309/ajg.0000000000000062
   PubMed Web of Science ®Google Scholar
• Targownik LE, Leslie WD, Carr R, et al. Longitudinal change in bone mineral density in a population-based cohort of patients with inflammatory bowel disease. Calcif Tissue Int. 2012 Nov;91(5):356–363. doi: 10.1007/s00223-012-9650-1
   PubMed Web of Science ®Google Scholar
• van Staa TP, Cooper C, Brusse LS, et al. Inflammatory bowel disease and the risk of fracture. Gastroenterology. 2003 Dec;125(6):1591–1597. doi: 10.1053/j.gastro.2003.09.027
   PubMed Web of Science ®Google Scholar
• Vázquez MA, Lopez E, Montoya MJ, et al. Vertebral fractures in patients with inflammatory bowel disease compared with a healthy population: a prospective case-control study. BMC Gastroenterol. 2012 May 14;12(1):47. doi: 10.1186/1471-230X-12-47
   PubMedGoogle Scholar
• Targownik LE, Bernstein CN, Nugent Z, et al. Inflammatory bowel disease has a small effect on bone mineral density and risk for osteoporosis. Clin Gastroenterol Hepatol. 2013 Mar;11(3):278–285. doi: 10.1016/j.cgh.2012.10.022
   PubMed Web of Science ®Google Scholar
• Komaki Y, Komaki F, Micic D, et al. Risk of fractures in inflammatory bowel diseases: a systematic review and meta-analysis. J Clin Gastroenterol. 2019 Jul;53(6):441–448. doi: 10.1097/MCG.0000000000001031
   PubMed Web of Science ®Google Scholar
• Lamb EJ, Wong T, Smith DJ, et al. Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2002 Nov;16(11):1895–1902. doi: 10.1046/j.1365-2036.2002.01363.x
   PubMed Web of Science ®Google Scholar
• Casals-Seoane F, Chaparro M, Maté J, et al. Clinical course of bone metabolism Disorders in patients with inflammatory bowel disease: A 5-year prospective study. Inflamm Bowel Dis. 2016 Aug;22(8):1929–1936. doi: 10.1097/MIB.0000000000000815
   PubMed Web of Science ®Google Scholar
• Even Dar R, Mazor Y, Karban A, et al. Risk factors for low bone density in inflammatory bowel disease: use of glucocorticoids, low body mass index, and smoking. Dig Dis. 2019;37(4):284–290. doi: 10.1159/000496935
   PubMed Web of Science ®Google Scholar
• de Silva PA, Karunanayake AL, Dissanayaka TGI, et al. Osteoporosis in adult Sri Lankan inflammatory bowel disease patients. World J Gastroenterol. 2009 Jul 28;15(28):3528–3531. doi: 10.3748/wjg.15.3528
   PubMed Web of Science ®Google Scholar
• Vogelsang H, Ferenci P, Woloszczuk W, et al. Bone disease in vitamin D-deficient patients with Crohn’s disease. Dig Dis Sci. 1989 Jul;34(7):1094–1099. doi: 10.1007/BF01536381
   PubMed Web of Science ®Google Scholar
• Sohn J, Chang EJ, Yang HR. Vitamin D status and bone mineral density in children with inflammatory bowel disease compared to those with functional abdominal pain. J Korean Med Sci. 2017 Jun;32(6):961–967. doi: 10.3346/jkms.2017.32.6.961
   PubMed Web of Science ®Google Scholar
• Frei P, Fried M, Hungerbuhler V, et al. Analysis of risk factors for low bone mineral density in inflammatory bowel disease. Digestion. 2006;73(1):40–46. doi: 10.1159/000092013
   PubMed Web of Science ®Google Scholar
• Targownik LE, Bernstein CN, Nugent Z, et al. Inflammatory bowel disease and the risk of fracture after controlling for FRAX. J Bone Miner Res. 2013 May;28(5):1007–1013. doi: 10.1002/jbmr.1848
   PubMed Web of Science ®Google Scholar
• Reffitt DM, Meenan J, Sanderson JD, et al. Bone density improves with disease remission in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2003 Dec;15(12):1267–1273. doi: 10.1097/00042737-200312000-00003
   PubMed Web of Science ®Google Scholar
• Tilg H, Moschen AR, Kaser A, et al. Gut, inflammation and osteoporosis: basic and clinical concepts. Gut. 2008 May;57(5):684–694. doi: 10.1136/gut.2006.117382
   PubMed Web of Science ®Google Scholar
• Bastos CM, Araújo IM, Nogueira-Barbosa MH, et al. Reduced bone mass and preserved marrow adipose tissue in patients with inflammatory bowel diseases in long-term remission. Osteoporos Int. 2017 Jul;28(7):2167–2176. doi: 10.1007/s00198-017-4014-3
   PubMed Web of Science ®Google Scholar
• Ashcroft AJ, Cruickshank SM, Croucher PI, et al. Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. Immunity. 2003 Dec;19(6):849–861. doi: 10.1016/S1074-7613(03)00326-1
   PubMed Web of Science ®Google Scholar
• Theill LE, Boyle WJ, Penninger JM. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol. 2002;20:795–823. doi: 10.1146/annurev.immunol.20.100301.064753
   PubMed Web of Science ®Google Scholar
• Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997 Apr 18;89(2):309–319. doi: 10.1016/S0092-8674(00)80209-3
   PubMed Web of Science ®Google Scholar
• Locatelli V, Bianchi VE. Effect of GH/IGF-1 on bone metabolism and osteoporsosis. Int J Endocrinol. 2014;2014:1–25. doi: 10.1155/2014/235060
   Web of Science ®Google Scholar
• Dixit M, Poudel SB, Yakar S. Effects of GH/IGF axis on bone and cartilage. Mol Cell Endocrinol. 2021 Jan 1;519:111052. doi: 10.1016/j.mce.2020.111052
   PubMed Web of Science ®Google Scholar
• Fiorelli G, Formigli L, Zecchi Orlandini S, et al. Characterization and function of the receptor for IGF-I in human preosteoclastic cells. Bone. 1996 Mar;18(3):269–276. doi: 10.1016/8756-3282(95)00485-8
   PubMed Web of Science ®Google Scholar
• Bikle D, Majumdar S, Laib A, et al. The skeletal structure of insulin-like growth factor I-deficient mice. J Bone Miner Res. 2001 Dec;16(12):2320–2329. doi: 10.1359/jbmr.2001.16.12.2320
   PubMed Web of Science ®Google Scholar
• Brixen K, Kassem M, Nielsen HK, et al. Short-term treatment with growth hormone stimulates osteoblastic and osteoclastic activity in osteopenic postmenopausal women: a dose response study. J Bone Miner Res. 1995 Dec;10(12):1865–1874. doi: 10.1002/jbmr.5650101205
   PubMed Web of Science ®Google Scholar
• Ezzat S, Melmed S, Endres D, et al. Biochemical assessment of bone formation and resorption in acromegaly. J Clin Endocrinol Metab. 1993 Jun;76(6):1452–1457. doi: 10.1210/jcem.76.6.8501150
   PubMed Web of Science ®Google Scholar
• Marazuela M, Astigarraga B, Tabuenca MJ, et al. Serum bone Gla protein as a marker of bone turnover in acromegaly. Calcif Tissue Int. 1993 Jun;52(6):419–421. doi: 10.1007/BF00571329
   PubMed Web of Science ®Google Scholar
• Langlois JA, Rosen CJ, Visser M, et al. Association between insulin-like growth factor I and bone mineral density in older women and men: the Framingham Heart study. J Clin Endocrinol Metab. 1998 Dec;83(12):4257–4262. doi: 10.1210/jc.83.12.4257
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Kanatani M, Yamauchi M, et al. Serum levels of insulin-like growth factor (IGF); IGF-binding proteins-3, -4, and -5; and their relationships to bone mineral density and the risk of vertebral fractures in postmenopausal women. Calcif Tissue Int. 2006 Jan;78(1):18–24. doi: 10.1007/s00223-005-0163-z
   PubMed Web of Science ®Google Scholar
• Seck T, Scheidt-Nave C, Leidig-Bruckner G, et al. Low serum concentrations of insulin-like growth factor I are associated with femoral bone loss in a population-based sample of postmenopausal women. Clin Endocrinol (Oxf). 2001 Jul;55(1):101–106. doi: 10.1046/j.1365-2265.2001.01278.x
   PubMed Web of Science ®Google Scholar
• Vanderschueren D, Gaytant J, Boonen S, et al. Androgens and bone. Curr Opin Endocrinol Diabetes Obes. 2008 Jun;15(3):250–254. doi: 10.1097/MED.0b013e3282fe6ca9
   PubMedGoogle Scholar
• Leslie WD, Miller N, Rogala L, et al. Vitamin D status and bone density in recently diagnosed inflammatory bowel disease: the Manitoba IBD cohort study. Am J Gastroenterol. 2008 Jun;103(6):1451–1459. doi: 10.1111/j.1572-0241.2007.01753.x
   PubMed Web of Science ®Google Scholar
• Steell L, Gray SR, Russell RK, et al. Pathogenesis of Musculoskeletal deficits in children and adults with inflammatory bowel disease. Nutrients. 2021 Aug 23;13(8):2899. doi: 10.3390/nu13082899
   PubMed Web of Science ®Google Scholar
• Compston JE. Sex steroids and bone. Physiol Rev. 2001 Jan;81(1):419–447. doi: 10.1152/physrev.2001.81.1.419
   PubMed Web of Science ®Google Scholar
• Riggs BL. The mechanisms of estrogen regulation of bone resorption. J Clin Invest. 2000 Nov;106(10):1203–1204. doi: 10.1172/JCI11468
   PubMed Web of Science ®Google Scholar
• Burrelli Scotti G, Afferri MT, De Carolis A, et al. Factors affecting vitamin D deficiency in active inflammatory bowel diseases. Dig Liver Dis. 2019 May;51(5):657–662. doi: 10.1016/j.dld.2018.11.036
   PubMedGoogle Scholar
• Moschen AR, Kaser A, Enrich B, et al. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut. 2005 Apr;54(4):479–487. doi: 10.1136/gut.2004.044370
   PubMed Web of Science ®Google Scholar
• Franchimont N, Reenaers C, Lambert C, et al. Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn’s disease patients. Clin Exp Immunol. 2004 Dec;138(3):491–498. doi: 10.1111/j.1365-2249.2004.02643.x
   PubMed Web of Science ®Google Scholar
• Liu Z, Colpaert S, D’Haens GR, et al. Hyperexpression of CD40 ligand (CD154) in inflammatory bowel disease and its contribution to pathogenic cytokine production. J Immunol. 1999 Oct 1;163(7):4049–4057. doi: 10.4049/jimmunol.163.7.4049
   PubMed Web of Science ®Google Scholar
• Miheller P, Muzes G, Rácz K, et al. Changes of OPG and RANKL concentrations in Crohn’s disease after infliximab therapy. Inflamm Bowel Dis. 2007 Nov;13(11):1379–1384. doi: 10.1002/ibd.20234
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Sargent M, Leslie WD. Serum osteoprotegerin is increased in Crohn’s disease: a population-based case control study. Inflamm Bowel Dis. 2005 Apr;11(4):325–330. doi: 10.1097/01.MIB.0000164015.60795.ca
   PubMed Web of Science ®Google Scholar
• Kwan Tat S, Padrines M, Théoleyre S, et al. IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev. 2004 Feb;15(1):49–60. doi: 10.1016/j.cytogfr.2003.10.005
   PubMed Web of Science ®Google Scholar
• Krela-Kaźmierczak I, Szymczak-Tomczak A, Łykowska-Szuber L, et al. Interleukin 6, osteoprotegerin, sRANKL and bone metabolism in inflammatory bowel diseases. Adv Clin Exp Med. 2018 Apr;27(4):449–453. doi: 10.17219/acem/75675
   PubMed Web of Science ®Google Scholar
• Suda T, Takahashi N, Udagawa N, et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev. 1999 Jun;20(3):345–357. doi: 10.1210/edrv.20.3.0367
   PubMed Web of Science ®Google Scholar
• Marahleh A, Kitaura H, Ohori F, et al. TNF-α directly Enhances osteocyte RANKL expression and promotes osteoclast formation. Front Immunol. 2019;10:2925. doi: 10.3389/fimmu.2019.02925
   PubMed Web of Science ®Google Scholar
• Luo G, Li F, Li X, et al. TNF‑α and RANKL promote osteoclastogenesis by upregulating RANK via the NF‑κB pathway. Mol Med Rep. 2018 May;17(5):6605–6611. doi: 10.3892/mmr.2018.8698
   PubMed Web of Science ®Google Scholar
• Agrawal M, Arora S, Li J, et al. Bone, inflammation, and inflammatory bowel disease. Curr Osteoporos Rep. 2011 Dec;9(4):251–257. doi: 10.1007/s11914-011-0077-9
   PubMedGoogle Scholar
• Nemetz A, Tóth M, García-González MA, et al. Allelic variation at the interleukin 1beta gene is associated with decreased bone mass in patients with inflammatory bowel diseases. Gut. 2001 Nov;49(5):644–649. doi: 10.1136/gut.49.5.644
   PubMed Web of Science ®Google Scholar
• Littlewood AJ, Russell J, Harvey GR, et al. The modulation of the expression of IL-6 and its receptor in human osteoblasts in vitro. Endocrinology. 1991 Sep;129(3):1513–1520. doi: 10.1210/endo-129-3-1513
   PubMed Web of Science ®Google Scholar
• Franchimont N, Rydziel S, Canalis E. Interleukin 6 is autoregulated by transcriptional mechanisms in cultures of rat osteoblastic cells. J Clin Invest. 1997 Oct 1;100(7):1797–1803. doi: 10.1172/JCI119707
   PubMed Web of Science ®Google Scholar
• Sylvester FA, Wyzga N, Hyams JS, et al. Effect of Crohn’s disease on bone metabolism in vitro: a role for interleukin-6. J Bone Miner Res. 2002 Apr;17(4):695–702. doi: 10.1359/jbmr.2002.17.4.695
   PubMed Web of Science ®Google Scholar
• Kung Sutherland MS, Lipps SG, Patnaik N, et al. SP500263, a novel SERM, blocks osteoclastogenesis in a human bone cell model: role of IL-6 and GM-CSF. Cytokine. 2003 Jul;23(1–2):1–14. doi: 10.1016/S1043-4666(03)00179-0
   PubMed Web of Science ®Google Scholar
• Bennett CN, Longo KA, Wright WS, et al. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3324–3329. doi: 10.1073/pnas.0408742102
   PubMed Web of Science ®Google Scholar
• Stevens JR, Miranda-Carboni GA, Singer MA, et al. Wnt10b deficiency results in age-dependent loss of bone mass and progressive reduction of mesenchymal progenitor cells. J Bone Miner Res. 2010 Oct;25(10):2138–2147. doi: 10.1002/jbmr.118
   PubMed Web of Science ®Google Scholar
• Wend P, Wend K, Krum SA, et al. The role of WNT10B in physiology and disease. Acta Physiol (Oxf). 2012 Jan;204(1):34–51. doi: 10.1111/j.1748-1716.2011.02296.x
   PubMed Web of Science ®Google Scholar
• Casanova MJ, Chaparro M, Molina B, et al. Prevalence of malnutrition and nutritional Characteristics of patients with inflammatory bowel disease. J Crohns Colitis. 2017 Dec 4;11(12):1430–1439. doi: 10.1093/ecco-jcc/jjx102
   PubMed Web of Science ®Google Scholar
• Balestrieri P, Ribolsi M, Guarino MPL, et al. Nutritional Aspects in inflammatory bowel diseases. Nutrients. 2020 Jan 31;12(2):372. doi: 10.3390/nu12020372
   PubMed Web of Science ®Google Scholar
• Bischoff SC, Herrmann A, Göke M, et al. Altered bone metabolism in inflammatory bowel disease. Am J Gastroenterol. 1997 Jul;92(7):1157–1163.
   PubMed Web of Science ®Google Scholar
• Bruscoli S, Febo M, Riccardi C, et al. Glucocorticoid therapy in inflammatory bowel disease: Mechanisms and clinical practice. Front Immunol. 2021;12:691480. doi: 10.3389/fimmu.2021.691480
   PubMed Web of Science ®Google Scholar
• Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on glucocorticoid-induced osteoporosis. Arthritis Rheum. 2001 Jul;44(7):1496–1503. doi: 10.1002/1529-0131(200107)44:7<1496:AID-ART271>3.0.CO;2-5
   PubMedGoogle Scholar
• Van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000 Jun;15(6):993–1000. doi: 10.1359/jbmr.2000.15.6.993
   PubMed Web of Science ®Google Scholar
• Natsui K, Tanaka K, Suda M, et al. High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass. Osteoporos Int. 2006 Jan;17(1):105–108. doi: 10.1007/s00198-005-1923-3
   PubMed Web of Science ®Google Scholar
• Canalis E. Clinical review 83: Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab. 1996 Oct;81(10):3441–3447. doi: 10.1210/jc.81.10.3441
   PubMed Web of Science ®Google Scholar
• Canalis E, Mazziotti G, Giustina A, et al. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007 Oct;18(10):1319–1328. doi: 10.1007/s00198-007-0394-0
   PubMed Web of Science ®Google Scholar
• Canalis E. Mechanisms of glucocorticoid action in bone. Curr Osteoporos Rep. 2005 Sep;3(3):98–102. doi: 10.1007/s11914-005-0017-7
   PubMedGoogle Scholar
• Hofbauer LC, Gori F, Riggs BL, et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology. 1999 Oct;140(10):4382–4389. doi: 10.1210/endo.140.10.7034
   PubMed Web of Science ®Google Scholar
• Rubin J, Biskobing DM, Jadhav L, et al. Dexamethasone promotes expression of Membrane-Bound macrophage colony-stimulating factor in Murine osteoblast-like cells 1. Endocrinology. 1998 Mar;139(3):1006–1012. doi: 10.1210/endo.139.3.5778
   PubMed Web of Science ®Google Scholar
• von Scheven E, Corbin KJ, Stefano S, et al. Glucocorticoid-associated osteoporosis in chronic inflammatory diseases: epidemiology, mechanisms, diagnosis, and treatment. Curr Osteoporos Rep. 2014 Sep;12(3):289–299. doi: 10.1007/s11914-014-0228-x
   PubMed Web of Science ®Google Scholar
• Epstein S, Inzerillo AM, Caminis J, et al. Disorders associated with acute rapid and severe bone loss. J Bone Miner Res. 2003 Dec;18(12):2083–2094. doi: 10.1359/jbmr.2003.18.12.2083
   PubMed Web of Science ®Google Scholar
• De Vries F, Bracke M, Leufkens HG, et al. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum. 2007 Jan;56(1):208–214. doi: 10.1002/art.22294
   PubMed Web of Science ®Google Scholar
• van Staa TP, Leufkens HG, Abenhaim L, et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford). 2000 Dec;39(12):1383–1389. doi: 10.1093/rheumatology/39.12.1383
   PubMed Web of Science ®Google Scholar
• van Staa PT, Leufkens TPV, Staa HG, et al. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002 Oct;13(10):777–787. doi: 10.1007/s001980200108
   PubMed Web of Science ®Google Scholar
• Schoon EJ, Bollani S, Mills PR, et al. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn’s disease. Clin Gastroenterol Hepatol. 2005 Feb;3(2):113–121. doi: 10.1016/S1542-3565(04)00662-7
   PubMed Web of Science ®Google Scholar
• Fletcher J, Cooper SC, Ghosh S, et al. The role of vitamin D in inflammatory bowel disease: Mechanism to management. Nutrients. 2019 May 7;11(5):1019. doi: 10.3390/nu11051019
   PubMed Web of Science ®Google Scholar
• Frigstad SO, Høivik M, Jahnsen J, et al. Vitamin D deficiency in inflammatory bowel disease: prevalence and predictors in a Norwegian outpatient population. Scand J Gastroenterol. 2017 Jan;52(1):100–106. doi: 10.1080/00365521.2016.1233577
   PubMed Web of Science ®Google Scholar
• Caviezel D, Maissen S, Niess JH, et al. High prevalence of vitamin D deficiency among patients with inflammatory bowel disease. Inflamm Intest Dis. 2018 Jul;2(4):200–210. doi: 10.1159/000489010
   PubMedGoogle Scholar
• Vernia P, Loizos P, Di Giuseppantonio I, et al. Dietary calcium intake in patients with inflammatory bowel disease. J Crohns Colitis. 2014 Apr;8(4):312–317. doi: 10.1016/j.crohns.2013.09.008
   PubMed Web of Science ®Google Scholar
• Kabbani TA, Koutroubakis IE, Schoen RE, et al. Association of vitamin D level with clinical status in inflammatory bowel disease: A 5-year longitudinal study. Am J Gastroenterol. 2016 May;111(5):712–719. doi: 10.1038/ajg.2016.53
   PubMed Web of Science ®Google Scholar
• Bours PH, Wielders JP, Vermeijden JR, et al. Seasonal variation of serum 25-hydroxyvitamin D levels in adult patients with inflammatory bowel disease. Osteoporos Int. 2011 Nov;22(11):2857–2867. doi: 10.1007/s00198-010-1484-y
   PubMed Web of Science ®Google Scholar
• Jørgensen SP, Hvas CL, Agnholt J, et al. Active Crohn’s disease is associated with low vitamin D levels. J Crohns Colitis. 2013 Nov;7(10):e407–13. doi: 10.1016/j.crohns.2013.01.012
   PubMedGoogle Scholar
• Garg M, Rosella O, Lubel JS, et al. Association of circulating vitamin D concentrations with intestinal but not systemic inflammation in inflammatory bowel disease. Inflamm Bowel Dis. 2013 Nov;19(12):2634–2643. doi: 10.1097/01.MIB.0000436957.77533.b2
   PubMed Web of Science ®Google Scholar
• Abitbol V, Mary JY, Roux C, et al. Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride. Aliment Pharmacol Ther. 2002 May;16(5):919–927. doi: 10.1046/j.1365-2036.2002.01247.x
   PubMed Web of Science ®Google Scholar
• Vogelsang H, Ferenci P, Resch H, et al. Prevention of bone mineral loss in patients with Crohn’s disease by long-term oral vitamin D supplementation. Eur J Gastroenterol Hepatol. 1995 Jul;7(7):609–614.
   PubMed Web of Science ®Google Scholar
• Benchimol EI, Ward LM, Gallagher JC, et al. Effect of calcium and vitamin D supplementation on bone mineral density in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007 Nov;45(5):538–545. doi: 10.1097/MPG.0b013e3180dca0cc
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Seeger LL, Anton PA, et al. A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. Aliment Pharmacol Ther. 1996 Oct;10(5):777–786. doi: 10.1046/j.1365-2036.1996.63205000.x
   PubMed Web of Science ®Google Scholar
• Bakker SF, Dik VK, Witte BI, et al. Increase in bone mineral density in strictly treated Crohn’s disease patients with concomitant calcium and vitamin D supplementation. J Crohns Colitis. 2013 Jun;7(5):377–384. doi: 10.1016/j.crohns.2012.06.003
   PubMed Web of Science ®Google Scholar
• Ghishan FK, Kiela PR. Advances in the understanding of mineral and bone metabolism in inflammatory bowel diseases. Am J Physiol Gastrointest Liver Physiol. 2011 Feb;300(2):G191–201. doi: 10.1152/ajpgi.00496.2010
   PubMed Web of Science ®Google Scholar
• Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev. 2001 Aug;22(4):477–501. doi: 10.1210/edrv.22.4.0437
   PubMed Web of Science ®Google Scholar
• Olczyk M, Czkwianianc E, Socha-Banasiak A. Metabolic bone Disorders in children with inflammatory bowel diseases. Life. 2022 Mar 15;12(3):423. doi: 10.3390/life12030423
   PubMedGoogle Scholar
• Gordon RJ, Gordon CM. Bone health in pediatric patients with IBD: What is New? Curr Osteoporos Rep. 2021 Aug;19(4):429–435. doi: 10.1007/s11914-021-00691-x
   PubMed Web of Science ®Google Scholar
• Kao KT, Denker M, Zacharin M, et al. Pubertal abnormalities in adolescents with chronic disease. Best Pract Res Clin Endocrinol Metab. 2019 Jun;33(3):101275. doi: 10.1016/j.beem.2019.04.009
   PubMed Web of Science ®Google Scholar
• Laakso S, Valta H, Verkasalo M, et al. Compromised peak bone mass in patients with inflammatory bowel disease–a prospective study. J Pediatr. 2014 Jun;164(6):1436–43.e1. doi: 10.1016/j.jpeds.2014.01.073
   PubMed Web of Science ®Google Scholar
• DeBoer MD, Denson LA. Delays in puberty, growth, and accrual of bone mineral density in pediatric Crohn’s disease: despite temporal changes in disease severity, the need for monitoring remains. J Pediatr. 2013 Jul;163(1):17–22. doi: 10.1016/j.jpeds.2013.02.010
   PubMed Web of Science ®Google Scholar
• Wong SC, Catto-Smith AG, Zacharin M. Pathological fractures in paediatric patients with inflammatory bowel disease. Eur J Pediatr. 2014 Feb;173(2):141–151. doi: 10.1007/s00431-013-2174-5
   PubMed Web of Science ®Google Scholar
• Ward LM, Ma J, Rauch F, et al. Musculoskeletal health in newly diagnosed children with Crohn’s disease. Osteoporos Int. 2017 Nov;28(11):3169–3177. doi: 10.1007/s00198-017-4159-0
   PubMed Web of Science ®Google Scholar
• Sylvester FA, Wyzga N, Hyams JS, et al. Natural history of bone metabolism and bone mineral density in children with inflammatory bowel disease. Inflamm Bowel Dis. 2007 Jan;13(1):42–50. doi: 10.1002/ibd.20006
   PubMed Web of Science ®Google Scholar
• Dubner SE, Shults J, Baldassano RN, et al. Longitudinal assessment of bone density and structure in an incident cohort of children with Crohn’s disease. Gastroenterology. 2009 Jan;136(1):123–130. doi: 10.1053/j.gastro.2008.09.072
   PubMed Web of Science ®Google Scholar
• Ward LM, Rauch F, Matzinger MA, et al. Iliac bone histomorphometry in children with newly diagnosed inflammatory bowel disease. Osteoporos Int. 2010 Feb;21(2):331–337. doi: 10.1007/s00198-009-0969-z
   PubMed Web of Science ®Google Scholar
• Werkstetter KJ, Schatz SB, Alberer M, et al. Influence of exclusive enteral nutrition therapy on bone density and geometry in newly diagnosed pediatric Crohn’s disease patients. Ann Nutr Metab. 2013;63(1–2):10–16. doi: 10.1159/000350369
   PubMed Web of Science ®Google Scholar
• Sylvester FA, Leopold S, Lincoln M, et al. A two-year longitudinal study of persistent lean tissue deficits in children with Crohn’s disease. Clin Gastroenterol Hepatol. 2009 Apr;7(4):452–455. doi: 10.1016/j.cgh.2008.12.017
   PubMed Web of Science ®Google Scholar
• van der Eerden BC, Karperien M, Wit JM, et al. Systemic and local regulation of the growth plate. Endocr Rev. 2003 Dec;24(6):782–801. doi: 10.1210/er.2002-0033
   PubMed Web of Science ®Google Scholar
• Olney RC. Regulation of bone mass by growth hormone. Med Pediatr Oncol. 2003 Sep;41(3):228–234. doi: 10.1002/mpo.10342
   PubMedGoogle Scholar
• DeBoer MD, Lee AM, Herbert K, et al. Increases in IGF-1 after anti-TNF-α therapy are associated with bone and muscle accrual in pediatric Crohn disease. J Clin Endocrinol Metab. 2018 Mar 1;103(3):936–945. doi: 10.1210/jc.2017-01916
   PubMed Web of Science ®Google Scholar
• Wong SC, Smyth A, McNeill E, et al. The growth hormone insulin-like growth factor 1 axis in children and adolescents with inflammatory bowel disease and growth retardation. Clin Endocrinol (Oxf). 2010 Aug;73(2):220–228. doi: 10.1111/j.1365-2265.2010.03799.x
   PubMed Web of Science ®Google Scholar
• Sanderson IR. Growth problems in children with IBD. Nat Rev Gastroenterol Hepatol. 2014 Oct;11(10):601–610. doi: 10.1038/nrgastro.2014.102
   PubMed Web of Science ®Google Scholar
• Mazess RB, Barden HS. Measurement of bone by dual-photon absorptiometry (DPA) and dual-energy X-ray absorptiometry (DEXA). Ann Chir Gynaecol. 1988;77(5–6):197–203.
   PubMedGoogle Scholar
• Gordon H, Burisch J, Ellul P, et al. ECCO guidelines on extraintestinal Manifestations in inflammatory bowel disease. J Crohns Colitis. 2023 Jun 23;17:827–854. doi: 10.1093/ecco-jcc/jjac187.
   PubMed Web of Science ®Google Scholar
• LeBoff MS, Greenspan SL, Insogna KL, et al. The clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022 Oct;33(10):2049–2102. doi: 10.1007/s00198-021-05900-y
   PubMed Web of Science ®Google Scholar
• Pappa H, Thayu M, Sylvester F, et al. Skeletal health of children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2011 Jul;53(1):11–25. doi: 10.1097/MPG.0b013e31821988a3
   PubMed Web of Science ®Google Scholar
• Gordon CM, Leonard MB, Zemel BS. 2013 pediatric position development Conference: executive summary and reflections. J Clin Densitom. 2014 Apr;17(2):219–224. doi: 10.1016/j.jocd.2014.01.007
   PubMed Web of Science ®Google Scholar
• DeFilippis EM, Sockolow R, Barfield E. Health care maintenance for the pediatric patient with inflammatory bowel disease. Pediatrics. 2016 Sep;138(3). doi: 10.1542/peds.2015-1971.
   PubMed Web of Science ®Google Scholar
• Narula N, Dhillon A, Zhang D, et al. Enteral nutritional therapy for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2018 Apr 1;4(4):Cd000542. doi: 10.1002/14651858.CD000542.pub3
   PubMedGoogle Scholar
• Whitten KE, Leach ST, Bohane TD, et al. Effect of exclusive enteral nutrition on bone turnover in children with Crohn’s disease. J Gastroenterol. 2010 Apr;45(4):399–405. doi: 10.1007/s00535-009-0165-0
   PubMed Web of Science ®Google Scholar
• Soo J, Malik BA, Turner JM, et al. Use of exclusive enteral nutrition is just as effective as corticosteroids in newly diagnosed pediatric Crohn’s disease. Dig Dis Sci. 2013 Dec;58(12):3584–3591. doi: 10.1007/s10620-013-2855-y
   PubMed Web of Science ®Google Scholar
• Lev-Tzion R, Ben-Moshe T, Abitbol G, et al. The effect of nutritional therapy on bone mineral density and bone metabolism in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2021 Jun 1;72(6):877–882. doi: 10.1097/MPG.0000000000003073
   PubMed Web of Science ®Google Scholar
• Griffin LM, Thayu M, Baldassano RN, et al. Improvements in bone density and structure during anti-TNF-α therapy in pediatric Crohn’s disease. J Clin Endocrinol Metab. 2015 Jul;100(7):2630–2639. doi: 10.1210/jc.2014-4152
   PubMed Web of Science ®Google Scholar
• Pichler J, Hanslik A, Huber WD, et al. Paediatric patients with inflammatory bowel disease who received infliximab experienced improved growth and bone health. Acta Paediatr. 2014 Feb;103(2):e69–75. doi: 10.1111/apa.12448
   PubMed Web of Science ®Google Scholar
• Pichler J, Huber WD, Aufricht C, et al. Growth and bone health in paediatric patients with Crohn’s disease receiving subcutaneous tumor necrosis factor antibody. World J Gastroenterol. 2015 Jun 7;21(21):6613–6620. doi: 10.3748/wjg.v21.i21.6613
   PubMed Web of Science ®Google Scholar
• Hradsky O, Soucek O, Maratova K, et al. Supplementation with 2000 IU of Cholecalciferol is associated with improvement of trabecular bone mineral density and muscle Power in pediatric patients with IBD. Inflamm Bowel Dis. 2017 Apr;23(4):514–523. doi: 10.1097/MIB.0000000000001047
   PubMed Web of Science ®Google Scholar
• El Amrousy D, El Ashry H, Hodeib H, et al. Vitamin D in children with inflammatory bowel disease: a randomized controlled clinical trial. J Clin Gastroenterol. 2021 Oct 1;55(9):815–820. doi: 10.1097/MCG.0000000000001443
   PubMed Web of Science ®Google Scholar
• Gunter KB, Almstedt HC, Janz KF. Physical activity in childhood may be the key to optimizing lifespan skeletal health. Exerc Sport Sci Rev. 2012 Jan;40(1):13–21. doi: 10.1097/JES.0b013e318236e5ee
   PubMed Web of Science ®Google Scholar
• Vanhelst J, Vidal F, Turck D, et al. Physical activity is associated with improved bone health in children with inflammatory bowel disease. Clin Nutr. 2020 Jun;39(6):1793–1798. doi: 10.1016/j.clnu.2019.07.018
   PubMed Web of Science ®Google Scholar
• Trivić I, Sila S, Batoš AT, et al. Moderate-to-Vigorous physical activity is associated with higher bone mineral density in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2022 Jan 1;74(1):54–59. doi: 10.1097/MPG.0000000000003258
   PubMed Web of Science ®Google Scholar
• Moradkhani A, Beckman LJ, Tabibian JH. Health-related quality of life in inflammatory bowel disease: psychosocial, clinical, socioeconomic, and demographic predictors. J Crohns Colitis. 2013 Jul;7(6):467–473. doi: 10.1016/j.crohns.2012.07.012
   PubMed Web of Science ®Google Scholar
• Ng V, Millard W, Lebrun C, et al. Low-intensity exercise improves quality of life in patients with Crohn’s disease. Clin J Sport Med. 2007 Sep;17(5):384–388. doi: 10.1097/JSM.0b013e31802b4fda
   PubMed Web of Science ®Google Scholar
• Taylor K, Scruggs PW, Balemba OB, et al. Associations between physical activity, resilience, and quality of life in people with inflammatory bowel disease. Eur J Appl Physiol. 2018 Apr;118(4):829–836. doi: 10.1007/s00421-018-3817-z
   PubMed Web of Science ®Google Scholar
• Zhao X, Zhou C, Chen H, et al. Efficacy and safety of medical therapy for low bone mineral density in patients with Crohn disease: a systematic review with network meta-analysis. Medicine (Baltimore). 2017 Mar;96(11):e6378. doi: 10.1097/MD.0000000000006378
   PubMed Web of Science ®Google Scholar
• Yao L, Wang H, Dong W, et al. Efficacy and safety of bisphosphonates in management of low bone density in inflammatory bowel disease: a meta-analysis. Medicine (Baltimore). 2017 Jan;96(3):e5861. doi: 10.1097/MD.0000000000005861
   PubMed Web of Science ®Google Scholar
• Baroncelli GI, Bertelloni S. The use of bisphosphonates in pediatrics. Horm Res Paediatr. 2014;82(5):290–302. doi: 10.1159/000365889
   PubMed Web of Science ®Google Scholar
• Bhatt RN, Hibbert SA, Munns CF. The use of bisphosphonates in children: review of the literature and guidelines for dental management. Aust Dent J. 2014 Mar;59(1):9–19. doi: 10.1111/adj.12140
   PubMed Web of Science ®Google Scholar
• Yoon JH, Choi Y, Lee Y, et al. Efficacy and safety of intravenous pamidronate infusion for treating osteoporosis in children and adolescents. Ann Pediatr Endocrinol Metab. 2021 Jun;26(2):105–111. doi: 10.6065/apem.2040150.075
   PubMed Web of Science ®Google Scholar
• Sbrocchi AM, Forget S, Laforte D, et al. Zoledronic acid for the treatment of osteopenia in pediatric Crohn’s disease. Pediatr Int. 2010 Oct;52(5):754–761. doi: 10.1111/j.1442-200X.2010.03174.x
   PubMed Web of Science ®Google Scholar
• Simm PJ, Biggin A, Zacharin MR, et al. Consensus guidelines on the use of bisphosphonate therapy in children and adolescents. J Paediatr Child Health. 2018 Mar;54(3):223–233. doi: 10.1111/jpc.13768
   PubMed Web of Science ®Google Scholar
• Altowati MA, Shepherd S, McGrogan P, et al. Effects of recombinant human growth hormone in children with Crohn’s disease on the muscle-bone unit: a preliminary study. Horm Res Paediatr. 2018;90(2):128–131. doi: 10.1159/000492398
   PubMed Web of Science ®Google Scholar
• Hannon TS, DiMeglio LA, Pfefferkorn MD, et al. Effects of recombinant human growth hormone on protein turnover in the fasting and fed state in adolescents with Crohn disease. J Pediatr Endocrinol Metab. 2011;24(9–10):633–640. doi: 10.1515/JPEM.2011.308
   PubMed Web of Science ®Google Scholar
• Pappa HM, Saslowsky TM, Filip-Dhima R, et al. Efficacy and harms of nasal calcitonin in improving bone density in young patients with inflammatory bowel disease: a randomized, placebo-controlled, double-blind trial. Am J Gastroenterol. 2011 Aug;106(8):1527–1543. doi: 10.1038/ajg.2011.129
   PubMed Web of Science ®Google Scholar